Related Experiment Video

Updated: May 23, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system

Jeanne Tie1, Jayesh Desai

  • 1Royal Melbourne Hospital, Western Hospital, and Ludwig Institute for Cancer Research, Parkville, Victoria, Australia.

Critical Reviews in Oncogenesis
|April 5, 2012
PubMed

Insights

Targeting the vascular endothelial growth factor (VEGF) pathway inhibits tumor growth but faces challenges with efficacy and resistance. Identifying predictive biomarkers is crucial for advancing VEGF-targeted cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Angiogenesis, driven by vascular endothelial growth factor (VEGF) signaling, is essential for tumor growth and metastasis.
  • VEGF-targeted therapies, including antibodies and tyrosine kinase inhibitors, are clinically used to inhibit tumor neovascularization.
  • Current VEGF-targeted agents show limited efficacy and are prone to resistance, hindering their full potential.

Purpose of the Study:

  • To review the biology of VEGF signaling in cancer.
  • To discuss the clinical efficacy and resistance mechanisms of VEGF-targeted therapies.
  • To explore emerging predictive biomarkers for improved therapeutic strategies.

Main Methods:

  • Literature review of VEGF signaling pathways.
  • Analysis of clinical trial data for VEGF-targeted agents.
  • Examination of molecular mechanisms underlying therapeutic resistance.
  • Identification and evaluation of potential predictive biomarkers.

Main Results:

  • VEGF pathway is a key regulator of tumor angiogenesis.
  • VEGF-targeted therapies offer clinical benefits but are limited by modest efficacy and acquired resistance.
  • Mechanisms of resistance include alternative signaling pathways and tumor microenvironment adaptations.
  • Biomarkers are needed to predict patient response and resistance to VEGF-targeted treatments.

Conclusions:

  • VEGF signaling is a critical target in oncology.
  • Overcoming resistance and identifying predictive biomarkers are essential for optimizing VEGF-targeted cancer therapy.
  • Further research into biomarkers will guide the rational development of next-generation anti-angiogenic agents.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: